Cat. No.: DAB-0012762
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with recombinant human full-length prostatic acid phosphatase. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ACP3 |
| UniProt No. | P15309 |
| Gene ID | 55 |
| Gene Description | Prostatic Acid Phosphatase is a member of the histidine acid phosphatase family. It is a non-specific phosphatase that is capable of dephosphorylating tyrosine residues as well as phospholipids under mildly acidic conditions. ACPP has ecto-5'-nucleotidase activity in pain-sensing neurons where it converts AMP to adenosine, suppressing the pain response. ACPP occurs as two isoforms that are both heavily glycosylated. The secreted phosphatase is found predominantly in the prostate and seminal plasma, while the cellular isoform is broadly expressed at very low levels and is associated with the plasma and lysosomal membranes. Cellular PAP has been shown to dephosphorylate ErbB2 at various tyrosine residues effectively terminating signaling. Furthermore, the physical interaction between cPAP and ErbB2 appears to regulate androgen sensitivity in prostate cancer cells. Loss of cPAP in androgen-sensitive prostate cancer cells results in the development of a castration-resistant phenotype suggesting that ACPP plays a significant role in prostate cancer cell growth. ACPP is expressed in metastatic cells arising from prostate cancer - especially in prostate-derived bone metastasis - suggesting that it may be a relevant diagnostic indicator of prostate cancer re-emergence in bone. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
